Thyroid News and Research

RSS

UC Riverside evolutionary biologist reveals why tall people are more prone to cancer

For most cancers, risk increases dramatically with age. But what about the effect of having more cells in the body? Might taller people be more prone to cancer because they have more cells?

26 Oct 2018

Head and neck cancer survivors more likely to commit suicide

Despite improved survival rates among cancer patients, the risk of death by suicide remains high, especially among those treated for head and neck cancers.

25 Oct 2018

Study examines factors associated with fasting hyperglucagonemia in type 2 diabetes

A new study examined the relationship between fasting hyperglucagonemia -- which can negatively affect glucose metabolism in patients with type 2 diabetes -- and several biochemical and glycemic factors in subjects with T2D or in a nondiabetic control group.

24 Oct 2018

Tall people more likely to get cancers, finds study

A new study suggests that tall people are more likely to get cancers because they have more number of cells that can undergo dangerous mutations.

24 Oct 2018

Genentech’s combination therapy improves outcome in patients with non-squamous non-small cell lung cancer

Genentech, a member of the Roche Group, today announced positive results from the Phase III IMpower130 study of Tecentriq (atezolizumab) plus chemotherapy (carboplatin and Abraxane® [albumin-bound paclitaxel; nab-paclitaxel]) for the initial (first-line) treatment of people with previously untreated metastatic non-squamous non-small cell lung cancer.

22 Oct 2018

Combination of Opdivo and Yervoy shows four-year survival benefits in patients with advanced melanoma

Bristol-Myers Squibb Company today announced four-year data from the Phase 3 CheckMate -067 clinical trial - the longest follow-up to date - which continues to demonstrate durable, long-term survival benefits with the first-line combination of Opdivo (nivolumab) and Yervoy (ipilimumab), versus Yervoy alone, in patients with advanced melanoma.

22 Oct 2018

Merck presents MK-1454 Phase 1 data for treatment of advanced solid tumors or lymphomas

Merck, known as MSD outside the United States and Canada, today announced the first presentation of preliminary data from a Phase 1 clinical trial evaluating MK-1454, an investigational STING (stimulator of interferon genes) agonist, as monotherapy and in combination with KEYTRUDA (pembrolizumab), Merck's anti-PD-1 therapy, in patients with advanced solid tumors or lymphomas.

22 Oct 2018

Merck presents KEYNOTE-057 trial results for patients with high-risk non-muscle invasive bladder cancer

Merck, known as MSD outside the United States and Canada, today announced the first presentation of results from an interim analysis of KEYNOTE-057, a Phase 2 trial evaluating KEYTRUDA, Merck's anti-PD-1 therapy, for previously treated patients with high-risk non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ or CIS plus papillary disease (Cohort A).

22 Oct 2018

New pragmatic study launched to understand the effectiveness of new type 2 diabetes drug

HealthCore, Inc., the outcomes research subsidiary of Anthem, Inc. and Novo Nordisk Inc., which manufacturers the once weekly GLP-1 receptor agonist Ozempic (semaglutide), are working together to launch the first of its kind pragmatic study to understand the benefits of semaglutide as compared with all other available diabetes drugs in a real-world pragmatic clinical trial for Type 2 diabetes - one of the nation's fastest growing chronic diseases.

17 Oct 2018

Lab study shows effectiveness of potential therapy for treatment-resistant hypothyroidism

A new "metal-coordinated" drug-delivery technology potentially could be used to supplement the standard therapy for hypothyroidism, which affects nearly 10 million Americans, and many more patients worldwide, according to results of a study published in the journal Thyroid this month.

15 Oct 2018

Extension trial assesses benefit of switching from flash monitoring to RT-CGM for hypoglycemia

In follow-up to the I HART CGM study, which showed the benefit of real-time continuous glucose monitoring compared to flash monitoring for time spent in hypoglycemia among adults with type 1 diabetes at high hypoglycemia risk, researchers conducted an extension trial that assessed the effects of continuing RT-CGM or switching from flash to RT-CGM of the subsequent 8 weeks.

15 Oct 2018

Lab grown retinal cells provide clues to color blindness treatment

Researchers have grown human retinal cells in the laboratories and thus attempted to understand the basis of color vision and its development in humans. The results showed that certain hormones are essential for the development of color vision in humans and were published in the latest issue of the journal Science.

11 Oct 2018

Veracyte to present data demonstrating potential of Envisia Genomic Classifier to improve ILD diagnosis

Veracyte, Inc. announced the presentation of data demonstrating that the Envisia Genomic Classifier can help physicians more confidently diagnose interstitial lung disease (ILD), including idiopathic pulmonary fibrosis (IPF), without the need for surgery.

8 Oct 2018

New approach could lead to precise treatments for traumatic brain injury

Traumatic head injury can have widespread effects in the brain, but now scientists can look in real time at how head injury affects thousands of individual cells and genes simultaneously in mice.

5 Oct 2018

Columbia University announces winners of 2018 Louisa Gross Horwitz Prize

Columbia University has decided to award the Louisa Gross Horwitz Prize 2018.

24 Sep 2018

China NMPA approves LENVIMA for treatment of unresectable hepatocellular carcinoma

Eisai Co., Ltd. and Merck & Co., Inc., Kenilworth N.J., U.S.A., known as MSD outside of the United States and Canada, announced that the China National Medical Products Administration approved the kinase inhibitor LENVIMA (lenvatinib) as a single agent for the treatment of patients with unresectable hepatocellular carcinoma who have not received prior systemic therapy.

24 Sep 2018

Thyroid News and Research

UC Riverside evolutionary biologist reveals why tall people are more prone to cancer

Head and neck cancer survivors more likely to commit suicide

Study examines factors associated with fasting hyperglucagonemia in type 2 diabetes

Tall people more likely to get cancers, finds study

Genentech’s combination therapy improves outcome in patients with non-squamous non-small cell lung cancer

Combination of Opdivo and Yervoy shows four-year survival benefits in patients with advanced melanoma

Merck presents MK-1454 Phase 1 data for treatment of advanced solid tumors or lymphomas

Merck presents KEYNOTE-057 trial results for patients with high-risk non-muscle invasive bladder cancer

New pragmatic study launched to understand the effectiveness of new type 2 diabetes drug

Lab study shows effectiveness of potential therapy for treatment-resistant hypothyroidism

Extension trial assesses benefit of switching from flash monitoring to RT-CGM for hypoglycemia

Lab grown retinal cells provide clues to color blindness treatment

Veracyte to present data demonstrating potential of Envisia Genomic Classifier to improve ILD diagnosis

New approach could lead to precise treatments for traumatic brain injury

Columbia University announces winners of 2018 Louisa Gross Horwitz Prize

China NMPA approves LENVIMA for treatment of unresectable hepatocellular carcinoma

Tweaking nuclear pores could provide new avenue to battle against cancer

Study shows air pollution may be bad for the fetus

Endocrine Society announces winners of prestigious 2019 Laureate Awards

Link discovered between tumor genome changes and mortality risk across cancer types

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News